binds plasma cholesterol-rich lipoproteins and transports them into cells to clear plasma cholesterol1}. The synthesis of LDLreceptor is regulated, to a large extent, by a sterol-mediated negative feedback mechanismat the level of gene transcription2). Whencells are depleted of cholesterol, the LDLreceptor gene is actively transcribed, and cholesterol is rapidly cleared from plasma. On the other hand, when cholesterol accumulates in cells, the expression of LDLreceptor gene is repressed and plasma cholesterol level elevates. The inhibition of HMG-CoAreductase, a rate-limiting enzyme, in the cholesterol biosynthetic pathway depletes cellular cholesterol and activates LDLreceptor gene transcription, thereby lowering plasma cholesterol1*. The activation of LDLreceptor gene transcription might be advantageous for ameliorating an elevated level of plasma cholesterol. In order to find compoundsthat activate the transcription of the LDLreceptor, we screened buthanol extracts of microbial culture broths. The transcription from LDLreceptor promoter was assessed by a reporter assay using Chinese hamster ovary (CHO) cells transfected by a LDL receptor promoterluciferase gene construct. The expression of luciferase activity in the transfectant was up-and down-regulated when cultured in the presence of lovastatin, an HMGCoA reductase inhibitor, and LDL, respectively (data not shown). In the course of our screening, we isolated two active compounds which increased the luciferase activity from culture broths of unidentified actinomycete strains. NMRand MSdata identified these compounds with trichostatain A and herboxidiene ( Fig. 1) , which had been reported as an antifungal antibiotic and a herbicidal compound, respectively3A). As shown in Table  1 , these compoundsincreased luciferase activity more potently than lovastatain.
By examining 125I-LDL binding in an assay using humanhepatoma HepG2cells, we studied the effects of trichostatain A and herboxidiene on the amounts of LDLreceptor synthesized on cell surface. Trichostatatin A and herboxidiene increased the specific binding of 125I-LDL to LDL receptor by48% and 31% at 10"7m and 10"9 m, respectively, whereas lovastatin increased the specific binding by 17% at 10~6m, taking the result for the cells cultured in the absence of compoundsas 100%. The above result indicated that these compounds activated the synthesis of LDLreceptor.
It has been reported that trichostatin A inhibits histone deacetylase and induces hyperacetylation of histone to stimulate the expression of several genes5"71.
The activation of LDLreceptor gene transcription by trichostatin A might be attributed to the histone hyperacetylation. The mechanism of activation by herboxidienen is not clear and merits further studies.
To our knowledge, this is the first report that trichostatain A and herboxidiene up-regulate the gene expression of LDLreceptor.
Experimental
Reporter Assay
CHOcells were transfected with a plasmid construct containing human LDLreceptor promoter region ( -240 Tris-HCl (pH 7.5), 0.15m NaCl, 2mg of BSA per ml, and solubilized in 0.1 n NaOH, Total radioactivity was counted with liquid scintilator. Non-specific binding was measured by addition of 50-fold excess of non-radiolabeled LDL. The specific binding was obtained by subtracting the non-specific binding from total binding.
